Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001493152-26-034251
Filing Date
2026-07-22
Accepted
2026-07-22 16:40:34
Documents
14
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A form10-ka.htm   iXBRL 10-K/A 180799
2 EX-31.3 ex31-3.htm EX-31.3 6348
3 EX-31.4 ex31-4.htm EX-31.4 6040
  Complete submission text file 0001493152-26-034251.txt   456635

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bfri-20251231.xsd EX-101.SCH 3751
5 XBRL DEFINITION FILE bfri-20251231_def.xml EX-101.DEF 27775
6 XBRL LABEL FILE bfri-20251231_lab.xml EX-101.LAB 39247
7 XBRL PRESENTATION FILE bfri-20251231_pre.xml EX-101.PRE 26390
17 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 8950
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-40943 | Film No.: 261194184
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)